Cenderitide
Designer natriuretic peptide; heart failure research.
What it is
Cenderitide (also called CD-NP) is a designer chimeric peptide that combines portions of C-type natriuretic peptide (CNP) and dendroaspis natriuretic peptide (DNP, originally from green mamba snake venom). It was developed at the Mayo Clinic by John Burnett and colleagues for treatment of heart failure.
The chimeric design was intended to capture beneficial effects of multiple natriuretic peptides while addressing the limitations of single-peptide approaches. Cenderitide has been studied in clinical trials but has not advanced to broad clinical approval.
Mechanism of action
Activates both NPR-A and NPR-B receptors, producing vasodilation, natriuresis, and anti-fibrotic effects similar to other natriuretic peptides. The dual receptor activation was the conceptual basis for potential advantages over single-receptor approaches.
Clinical evidence
Phase II clinical trials in heart failure have been conducted. Results have shown the expected hemodynamic effects but commercial development has been limited.
Why we don’t prescribe it at The Tide
Cenderitide is an experimental cardiovascular drug for heart failure indications that fall outside our practice scope. The peptide is not appropriate for outpatient peptide clinic use.
Side effects and contraindications
Hypotension is the primary safety concern. Not appropriate for our practice setting.